320 related articles for article (PubMed ID: 22027420)
1. [Cancer immunotherapy: recent breakthroughs and perspectives].
Tartour E; Sandoval F; Bonnefoy JY; Fridman WH
Med Sci (Paris); 2011 Oct; 27(10):833-41. PubMed ID: 22027420
[TBL] [Abstract][Full Text] [Related]
2. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
3. [Vaccine strategies against melanoma].
Ghiringhelli F; Zitvogel L
Med Sci (Paris); 2006 Feb; 22(2):183-7. PubMed ID: 16457760
[TBL] [Abstract][Full Text] [Related]
4. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
6. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
Hwang C; Sanda MG
Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
[TBL] [Abstract][Full Text] [Related]
7. Cancer vaccines and immunotherapies: emerging perspectives.
Henderson RA; Mossman S; Nairn N; Cheever MA
Vaccine; 2005 Mar; 23(17-18):2359-62. PubMed ID: 15755628
[TBL] [Abstract][Full Text] [Related]
8. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
Moschella F; Proietti E; Capone I; Belardelli F
Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
[TBL] [Abstract][Full Text] [Related]
9. Melanoma and immunotherapy.
Eggermont AM; Schadendorf D
Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
[TBL] [Abstract][Full Text] [Related]
10. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
11. [Current status and future perspective of cancer vaccine development].
Sasada T; Itoh K
Gan To Kagaku Ryoho; 2011 Apr; 38(4):503-8. PubMed ID: 21498975
[TBL] [Abstract][Full Text] [Related]
12. Interventions that induce modifications in the tumor microenvironment.
Bernhard EJ
Cancer Radiother; 2011 Aug; 15(5):376-82. PubMed ID: 21571567
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer immunotherapy.
McNeel DG
Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy.
Schuster M; Nechansky A; Kircheis R
Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
[TBL] [Abstract][Full Text] [Related]
16. Cancer vaccines for established cancer: how to make them better?
Andrews DM; Maraskovsky E; Smyth MJ
Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006
[TBL] [Abstract][Full Text] [Related]
17. Melacine: an allogeneic melanoma tumor cell lysate vaccine.
Sosman JA; Sondak VK
Expert Rev Vaccines; 2003 Jun; 2(3):353-68. PubMed ID: 12903801
[TBL] [Abstract][Full Text] [Related]
18. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
19. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
Korman A; Yellin M; Keler T
Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
[TBL] [Abstract][Full Text] [Related]
20. Melanoma vaccines: achievements and perspectives.
Brichard VG; Gérard C
Forum (Genova); 2003; 13(2):144-54; quiz 189. PubMed ID: 14732881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
